TerminatedPHASE1, PHASE2NCT04604132
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Basilea Pharmaceutica
- Principal Investigator
- Manuel Häckl, MDBasilea Pharmaceutica International Ltd, Allschwil
- Intervention
- Derazantinib(drug)
- Enrollment
- 47 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (30)
- AdventHealth Cancer Institute, Orlando, Florida, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Fundación Favaloro para la Docencia e Investigación Médica, Buenos Aires, Argentina
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo, Ciudad Autonoma Buenos Aires, Argentina
- Monash Medical Centre Clayton, Clayton, Australia
- Peter MacCallum Cancer Centre, Melbourne, Australia
- The Alfred Hospital, Prahran, Australia
- UZA, Edegem, Belgium
- UZ Leuven, Leuven, Belgium
- AZ Delta, Menen, Belgium
- Liga Norte-Rio-Grandense Contra o Câncer, Natal, Rio Grande do Norte, Brazil
- Fundação Doutor Amaral Carvalho, Jaú, Brazil
- Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brazil
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Brazil
- Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04604132 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →